Top Markets
Coin of the day
IDL Diagnostics AB (publ) IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX
Rang in Aktien #32452
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops... Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Aktienkurs
$0.04367217
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$10.06M
Veränderung (1 Tag)
3.99%
Veränderung (1 Jahr)
-26.77%
Land
SE
Handel IDL Diagnostics AB (publ) (IDLDX)

Kategorie

Dividendenrendite-Verlauf für IDL Diagnostics AB (publ) (IDLDX)
Dividendenrendite (TTM) von IDL Diagnostics AB (publ) (Aktienkürzel: IDLDX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für IDL Diagnostics AB (publ) (IDLDX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber